Nasus Pharma presents intranasal epinephrine data at ACAAI annual scientific meeting
NSRX•Nasus Pharma will present NS002 anaphylaxis treatment data at the ACAAI annual scientific meeting in Phoenix, Nov. 12-16, 2026, including one oral presentation and three posters.
1. Meeting presentations
Nasus Pharma will present data on its investigational intranasal epinephrine powder, NS002, at the ACAAI annual scientific meeting in Phoenix from Nov. 12-16, 2026. An oral presentation on Nov. 14 will cover absorption in adults with allergic rhinitis; three posters on Nov. 13-14 will address absorption under nasal congestion, absorption with allergic rhinitis and anaphylaxis treatment priorities.
